All Stories

  1. The IRE1α Pathway Links Endoplasmic Reticulum Stress to Atherosclerosis‐Related Inflammation and Lipid Accumulation
  2. The Impact of Lipoprotein Apheresis on Inflammatory Factors: A Systematic Review and Meta‐Analysis
  3. Optimized Method for the Use of Polyethylene Glycol as Embedding Medium for Histological Studies
  4. Analysis of Mutational Burden of Mitochondrial Genome in Cells of Different Human Organs and Tissues
  5. Is Oxidized Low-Density Lipoprotein a Principal Actor in Atherogenesis?
  6. Mitochondrial Dysfunction Associated with mtDNA Mutation: Mitochondrial Genome Editing in Atherosclerosis Research
  7. Rheumatoid Arthritis: What Inflammation Do We Face?
  8. Use of Olives-derived Phytochemicals for Prevention and Treatment of Atherosclerosis: An Update
  9. Mitochondrial Dysfunction in Systemic Lupus Erythematosus: Insights and Therapeutic Potential
  10. Vitamin D in Primary Sjogren’s Syndrome (pSS) and the Identification of Novel Single-Nucleotide Polymorphisms Involved in the Development of pSS-Associated Diseases
  11. Role of Cathelicidins in Atherosclerosis and Associated Cardiovascular Diseases
  12. Molecular Aspects of Inflammation and Lipid Metabolism in Health and Disease: The Role of the Mitochondria
  13. Cholesteryl Ester Transfer Protein Variations and Cardiovascular Diseases
  14. Mitochondrial Genome Editing: Exploring the Possible Relationship of the Atherosclerosis-Associated Mutation m.15059G>A With Defective Mitophagy
  15. Is There a Relationship between Adverse Pregnancy Outcomes and Future Development of Atherosclerosis?
  16. Potential Use of Antioxidant Compounds for the Treatment of Inflammatory Bowel Disease
  17. Potential Application of the Plant-Derived Essential Oils for Atherosclerosis Treatment: Molecular Mechanisms and Therapeutic Potential
  18. Atheroprotective Aspects of Heat Shock Proteins
  19. Oligosaccharides as Potential Therapeutics against Atherosclerosis
  20. The Role of Selenium in Atherosclerosis Development, Progression, Prevention and Treatment
  21. Condition “Vasa Vasorum” in Patients with Thoracic Aortic Aneurysm
  22. Impaired Mitochondrial Function in T-Lymphocytes as a Result of Exposure to HIV and ART
  23. HDL-Based Therapy: Vascular Protection at All Stages
  24. Hypotheses on Atherogenesis Triggering: Does the Infectious Nature of Atherosclerosis Development Have a Substruction?
  25. Creation of Mitochondrial Disease Models Using Mitochondrial DNA Editing
  26. Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis
  27. The Role of Macrophages in the Pathogenesis of Atherosclerosis
  28. Mechanisms of the Wnt Pathways as a Potential Target Pathway in Atherosclerosis
  29. Sialic acid as the potential link between lipid metabolism and inflammation in the pathogenesis of atherosclerosis
  30. Targeting Mitochondrial Dynamics Proteins for the Development of Therapies for Cardiovascular Diseases
  31. Significance of Mitochondrial Dysfunction in the Progression of Multiple Sclerosis
  32. Effect of Glucose Levels on Cardiovascular Risk
  33. Atherosclerosis Specific Features in Chronic Kidney Disease (CKD)
  34. From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease
  35. The Role of Mitochondrial Abnormalities in Diabetic Cardiomyopathy
  36. Aging of Vascular System Is a Complex Process: The Cornerstone Mechanisms
  37. Interplay between Zn2+ Homeostasis and Mitochondrial Functions in Cardiovascular Diseases and Heart Ageing
  38. Cholesterol Transport Dysfunction and Its Involvement in Atherogenesis
  39. Modulating mTOR Signaling as a Promising Therapeutic Strategy for Atherosclerosis
  40. Molecular Pathogenesis and the Possible Role of Mitochondrial Heteroplasmy in Thoracic Aortic Aneurysm
  41. Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome
  42. Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis, and Treatment of Global Diseases
  43. The role of endoplasmic reticulum stress in atherosclerosis
  44. Thoracic Aortic Aneurysm and Factors Affecting Aortic Dissection
  45. Lipid Metabolism in Macrophages: Focus on Atherosclerosis
  46. Endoplasmic Reticulum Stress in Macrophages: The Vicious Circle of Lipid Accumulation and Pro-Inflammatory Response
  47. Cell and tissue markers of atherosclerosis
  48. Cholesterol metabolism in macrophages
  49. Signaling Pathways Potentially Responsible for Foam Cell Formation: Cholesterol Accumulation or Inflammatory Response—What is First?
  50. Signaling Pathways and Key Genes Involved in Regulation of foam Cell Formation in Atherosclerosis
  51. Role of Phagocytosis in the Pro-Inflammatory Response in LDL-Induced Foam Cell Formation; a Transcriptome Analysis
  52. Atherosclerosis prevention the role of special diets and functional food
  53. Prevention of atherosclerosis the role of special diets and functional foods
  54. Heteroplasmic Variants of Mitochondrial DNA in Atherosclerotic Lesions of Human Aortic Intima
  55. Genetic and Molecular Approaches to Drug Target Discovery for Treatment of the most Dangerous Diseases that are Rapidly Increasing Globally. Part II
  56. Genetic and Molecular Approaches to Drug Target Discovery for Treatment of the most Dangerous Diseases that are Rapidly Increasing Globally. Part I
  57. Transcriptional Characteristics of Activated Macrophages
  58. Glycosylation of human plasma lipoproteins reveals a high level of diversity, which directly impacts their functional properties
  59. The role of physical activity in the development of atherosclerotic lesions of the vascular wall
  60. Translation of Basic Research into Clinical Practice: Focus on Cell-Based Diagnostics and Therapy
  61. Diagnostics and Therapy of Human Diseases - Focus on Sialidases
  62. Current Approaches to Diagnostics and Therapies of Chronic Diseases: Focus on Molecular and Cell Biology
  63. HDL activates expression of genes stimulating cholesterol efflux in human monocyte-derived macrophages
  64. Sialidases: Therapeutic and Antiatherogenic Potential
  65. HDL-Targeting Therapeutics: Past, Present and Future
  66. Multiple-modified Low-Density Lipoprotein as Atherogenic Factor of Patients'; Blood: Development of Therapeutic Approaches to Reduce Blood Atherogenicity
  67. Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c
  68. Analysis of Apolipoprotein B Protein of Circulating Multiple-Modified Low-Density Lipoprotein
  69. Carbohydrate composition of circulating multiple-modified low-density lipoprotein
  70. Lipid composition of circulating multiple-modified low density lipoprotein
  71. Epigenetic factors in atherogenesis: MicroRNA
  72. Epigenetic factors in atherogenesis: microRNA
  73. Atherogenic modification of low-density lipoproteins
  74. Neuron density in the hippocampus in rat strains with contrasting nervous system excitability after prolonged emotional-pain stress